How can biotech startups best survive the 'valley of death'? Our experts from the WIPIT Life Sciences practice group, Benedikt Mahr, Britta Neß and Kai Grunwald, have analyzed some of the most important legal factors that help companies transform their academic innovations into clinical trials and a successful business. To learn more about these key survival factors, read their article in the special 'Life Sciences' edition of Venture Capital Magazine, available at VentureCapital Magazin 05/2025 | VentureCapital Magazin

‍